Advertisement

Linc00299/miR-490-3p/AURKA axis regulates cell growth and migration in atherosclerosis

  • Yong Liu
  • Yaqing Chen
  • Lili Tan
  • Hongmei Zhao
  • Nuan XiaoEmail author
Original Article
  • 6 Downloads

Abstract

Long non-coding RNA (lncRNA) plays a crucial role in regulating various cellular processes in atherosclerosis. The present study identified the regulation of Linc00299, via miR-490-3p targeting Aurora kinase A (AURKA), on migration and proliferation of endothelial cells and vascular smooth muscle cells (VSMCs) during atherosclerosis. The expression of RNAs was assessed by real-time PCR. The proliferation, apoptosis and migration were detected using MTT assay, Annexin V/PI staining and Transwell system, respectively. Bindings of Linc00299/miR-490-3p and subsequent miR-490-3p/AURKA were verified by luciferase and biotin pull-down assays. The protein expression of AURKA was detected by Western blotting. Expressions of Linc00299 and miR-490-3p were upregulated and downregulated in atherosclerosis patients, respectively. Both Linc00299 knockdown and miR-490-3p overexpression suppressed cell proliferation, increased apoptosis and inhibited migration of VSMCs and HUVECs. Linc00299 directly bound to miR-490-3p which targeted AURKA. The regulation of Linc00299 on expression of AURKA and proliferation and migration of VSMCs were dependent on miR-490-3p. Atherosclerosis-increased Linc00299 acts as a sponge of miR-490-3p to upregulate AURKA, and as a result increases proliferation and migration in VSMCs and HUVECs. Our study reveals an important effect of Linc00299/miR-490-3p/AURKA axis on regulating cell proliferation and migration in atherosclerosis.

Keywords

Atherosclerosis Linc00299 miR-490-3p AURKA Vascular smooth muscle cells 

Notes

Acknowledgements

This study was supported by the Health Planning Commission of Hebei Provincial Medical Research (NO 20180724), Baoding Science and Technology Project (NO 17ZF131) and Health Planning Commission and Finance Department of Hebei Provincial: Geriatric Disease Prevention and Control Project (NO 2017068879-204).

Compliance with ethical standards

Conflicts of interest

All authors disclose that they do not have any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations and grants or other funding. All the authors state that they have no conflicts of interest.

Human and animal rights

The study was approved by the Ethics Committee of Affiliated Hospital of Hebei University.

Informed consent

Written informed consent had been signed by all patients.

References

  1. 1.
    Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P, American Heart Association Council on E, Prevention Statistics C, Stroke Statistics S (2018) Heart disease and stroke statistics-2018 update: a report from the American heart association. Circulation 137:e67–e492Google Scholar
  2. 2.
    Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695CrossRefPubMedGoogle Scholar
  3. 3.
    Tabas I, Garcia-Cardena G, Owens GK (2015) Recent insights into the cellular biology of atherosclerosis. J Cell Biol 209:13–22CrossRefPubMedGoogle Scholar
  4. 4.
    Pober JS, Min W, Bradley JR (2009) Mechanisms of endothelial dysfunction, injury, and death. Annu Rev Pathol 4:71–95CrossRefPubMedGoogle Scholar
  5. 5.
    Mestas J, Ley K (2008) Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med 18:228–232CrossRefPubMedGoogle Scholar
  6. 6.
    Wang D, Uhrin P, Mocan A, Waltenberger B, Breuss JM, Tewari D, Mihaly-Bison J, Huminiecki L, Starzynski RR, Tzvetkov NT, Horbanczuk J, Atanasov AG (2018) Vascular smooth muscle cell proliferation as a therapeutic target. Part 1: molecular targets and pathways. Biotechnol Adv 36(6):1586–1607CrossRefPubMedGoogle Scholar
  7. 7.
    Jansen F, Li Q, Pfeifer A, Werner N (2017) Endothelial- and immune cell-derived extracellular vesicles in the regulation of cardiovascular health and disease. JACC Basic Transl Sci 2:790–807CrossRefPubMedGoogle Scholar
  8. 8.
    Quinn JJ, Chang HY (2016) Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet 17:47–62CrossRefPubMedGoogle Scholar
  9. 9.
    Uchida S, Dimmeler S (2015) Long noncoding RNAs in cardiovascular diseases. Circ Res 116:737–750CrossRefPubMedGoogle Scholar
  10. 10.
    Wang K, Liu F, Zhou LY, Long B, Yuan SM, Wang Y, Liu CY, Sun T, Zhang XJ, Li PF (2014) The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res 114:1377–1388CrossRefPubMedGoogle Scholar
  11. 11.
    Aryal B, Suarez Y (2018) Non-coding RNA regulation of endothelial and macrophage functions during atherosclerosis. Vascul Pharmacol.  https://doi.org/10.1016/j.vph.2018.03.001 PubMedGoogle Scholar
  12. 12.
    Jian L, Jian D, Chen Q, Zhang L (2016) Long noncoding RNAs in atherosclerosis. J Atheroscler Thromb 23:376–384CrossRefPubMedGoogle Scholar
  13. 13.
    Talkowski ME, Maussion G, Crapper L, Rosenfeld JA, Blumenthal I, Hanscom C, Chiang C, Lindgren A, Pereira S, Ruderfer D, Diallo AB, Lopez JP, Turecki G, Chen ES, Gigek C, Harris DJ, Lip V, An Y, Biagioli M, Macdonald ME, Lin M, Haggarty SJ, Sklar P, Purcell S, Kellis M, Schwartz S, Shaffer LG, Natowicz MR, Shen Y, Morton CC, Gusella JF, Ernst C (2012) Disruption of a large intergenic noncoding RNA in subjects with neurodevelopmental disabilities. Am J Hum Genet 91:1128–1134CrossRefPubMedGoogle Scholar
  14. 14.
    Yang J, Chen L, Yang J, Ding J, Rong H, Dong W, Li X (2012) High mobility group box-1 induces migration of vascular smooth muscle cells via TLR4-dependent PI3K/Akt pathway activation. Mol Biol Rep 39:3361–3367CrossRefPubMedGoogle Scholar
  15. 15.
    Li J, Zhang Z, Xiong L, Guo C, Jiang T, Zeng L, Li G, Wang J (2017) SNHG1 lncRNA negatively regulates miR-199a-3p to enhance CDK7 expression and promote cell proliferation in prostate cancer. Biochem Biophys Res Commun 487:146–152CrossRefPubMedGoogle Scholar
  16. 16.
    Zhang P, Cao L, Fan P, Mei Y, Wu M (2016) LncRNA-MIF, a c-Myc-activated long non-coding RNA, suppresses glycolysis by promoting Fbxw7-mediated c-Myc degradation. EMBO Rep 17:1204–1220CrossRefPubMedGoogle Scholar
  17. 17.
    Li P, Yang X, Yuan W, Yang C, Zhang X, Han J, Wang J, Deng X, Yang H, Li P, Tao J, Lu Q, Gu M (2018) CircRNA-Cdr1as exerts anti-oncogenic functions in bladder cancer by sponging microRNA-135a. Cell Physiol Biochem 46:1606–1616CrossRefPubMedGoogle Scholar
  18. 18.
    Boon RA, Jae N, Holdt L, Dimmeler S (2016) Long noncoding RNAs: from clinical genetics to therapeutic targets? J Am Coll Cardiol 67:1214–1226CrossRefPubMedGoogle Scholar
  19. 19.
    Blake J, Riddell A, Theiss S, Gonzalez AP, Haase B, Jauch A, Janssen JW, Ibberson D, Pavlinic D, Moog U, Benes V, Runz H (2014) Sequencing of a patient with balanced chromosome abnormalities and neurodevelopmental disease identifies disruption of multiple high risk loci by structural variation. PLoS ONE 9:e90894CrossRefPubMedGoogle Scholar
  20. 20.
    Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, Tramontano A, Bozzoni I (2011) A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 147:358–369CrossRefPubMedGoogle Scholar
  21. 21.
    Carmena M, Earnshaw WC, Glover DM (2015) The dawn of aurora kinase research: from fly genetics to the clinic. Front Cell Dev Biol 3:73CrossRefPubMedGoogle Scholar
  22. 22.
    Damodaran AP, Vaufrey L, Gavard O, Prigent C (2017) Aurora A kinase is a priority pharmaceutical target for the treatment of cancers. Trends Pharmacol Sci 38:687–700CrossRefPubMedGoogle Scholar
  23. 23.
    Otto T, Sicinski P (2017) Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer 17:93–115CrossRefPubMedGoogle Scholar
  24. 24.
    Vo TTL, Park JH, Seo JH, Lee EJ, Choi H, Bae SJ, Le H, An S, Lee HS, Wee HJ, Kim KW (2017) ARD1-mediated aurora kinase A acetylation promotes cell proliferation and migration. Oncotarget 8:57216–57230PubMedGoogle Scholar
  25. 25.
    Yuan Q, Sun T, Ye F, Kong W, Jin H (2017) MicroRNA-124-3p affects proliferation, migration and apoptosis of bladder cancer cells through targeting AURKA. Cancer Biomark 19:93–101CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  • Yong Liu
    • 1
  • Yaqing Chen
    • 1
  • Lili Tan
    • 1
  • Hongmei Zhao
    • 1
  • Nuan Xiao
    • 1
    Email author
  1. 1.Affiliated Hospital of Hebei UniversityBaodingChina

Personalised recommendations